Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$810.79K-$810.79KN/M vs Q1 2025 EPS Diluted-$0.07-$0.07N/M vs Q1 2025 Operating Income-$798,509N/M Operating Cash Flow$578,584N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end